Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs

被引:6
作者
Svedmyr, Anders [1 ]
Hack, Henrik [1 ]
Anderson, Brian J. [1 ]
机构
[1] Starship Childrens Hosp, Dept Anaesthesia, Pk Rd, Auckland 1023, New Zealand
关键词
anesthesia; antiviral; children; COVID-19; drug interactions; pharmacodynamics; HUMAN-IMMUNODEFICIENCY-VIRUS; CYP3A INHIBITION; PHARMACOKINETICS; LOPINAVIR/RITONAVIR; CLEARANCE; MIDAZOLAM; FENTANYL; PHARMACODYNAMICS; CYTOCHROME-P450; METABOLITE;
D O I
10.1111/pan.14529
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The protease inhibitor, ritonavir, is a strong inhibitor of CYP 3A. The drug is used for management of the human immunovirus and is currently part of an oral antiviral drug combination (nirmatrelvir-ritonavir) for the early treatment of SARS-2 COVID-19-positive patients aged 12 years and over who have recognized comorbidities. The CYP 3A enzyme system is responsible for clearance of numerous drugs used in anesthesia (e.g., alfentanil, fentanyl, methadone, rocuronium, bupivacaine, midazolam, ketamine). Ritonavir will have an impact on drug clearances that are dependent on ritonavir concentration, anesthesia drug intrinsic hepatic clearance, metabolic pathways, concentration-response relationship, and route of administration. Drugs with a steep concentration-response relationship (ketamine, midazolam, rocuronium) are mostly affected because small changes in concentration have major changes in effect response. An increase in midazolam concentration is observed after oral administration because CYP 3A in the gastrointestinal wall is inhibited, causing a large increase in relative bioavailability. Fentanyl infusion may be associated with a modest increase in plasma concentration and effect, but the large between subject variability of pharmacokinetic and pharmacodynamic concentration changes suggests it will have little impact on an individual patient, especially when used with adverse effect monitoring. It has been proposed that drugs that have no or only a small metabolic pathway involving the CYP 3A enzyme be used during anesthesia, for example, propofol, atracurium, remifentanil, and the volatile agents. That anesthesia approach denies children of drugs with considerable value. It is better that the inhibitory changes in clearance of these drugs are understood so that rational drug choices can be made to tailor drug use to the individual patient. Altered drug dose, anticipation of duration of effect, timing of administration, use of reversal agents and perioperative monitoring would better behoove children undergoing anesthesia.
引用
收藏
页码:1091 / 1099
页数:9
相关论文
共 49 条
  • [1] Scaling for size: some implications for paediatric anaesthesia dosing
    Anderson, BJ
    Meakin, GH
    [J]. PAEDIATRIC ANAESTHESIA, 2002, 12 (03): : 205 - 219
  • [2] A maturation model for midazolam clearance
    Anderson, Brian J.
    Larsson, Peter
    [J]. PEDIATRIC ANESTHESIA, 2011, 21 (03) : 302 - 308
  • [3] Tips and traps analyzing pediatric PK data
    Anderson, Brian J.
    Holford, Nick H. G.
    [J]. PEDIATRIC ANESTHESIA, 2011, 21 (03) : 222 - 237
  • [4] A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates
    Arora, Sumit
    Pansari, Amita
    Kilford, Peter J.
    Jamei, Masoud
    Turner, David B.
    Gardner, Iain
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (04) : 483 - 495
  • [5] PUPIL RESPONSE TO ALFENTANIL AND FENTANYL - A STUDY IN PATIENTS ANESTHETIZED WITH HALOTHANE
    ASBURY, AJ
    [J]. ANAESTHESIA, 1986, 41 (07) : 717 - 720
  • [6] The role of antiviral treatment in the COVID-19 pandemic
    Burki, Talha Khan
    [J]. LANCET RESPIRATORY MEDICINE, 2022, 10 (02) : E18 - E18
  • [7] Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results
    Chadwick, Ellen G.
    Capparelli, Edmund V.
    Yogev, Rarn
    Pinto, Jorge A.
    Robbins, Brian
    Rodman, John H.
    Chen, Jie
    Palumbo, Paul
    Serchuck, Leslie
    Smith, Elizabeth
    Hughes, Michael
    [J]. AIDS, 2008, 22 (02) : 249 - 255
  • [8] Concentration effect relationship of CYP3A inhibition by ritonavir in humans
    Eichbaum, Christine
    Cortese, Marianna
    Blank, Antje
    Burhenne, Juergen
    Mikus, Gerd
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (10) : 1795 - 1800
  • [9] Children on phenobarbital monotherapy requires more sedatives during MRI
    Eker, Hatice Evren
    Cok, Oya Yalcin
    Aribogan, Anis
    Arslan, Gulnaz
    [J]. PEDIATRIC ANESTHESIA, 2011, 21 (10) : 998 - 1002
  • [10] Timing of elective surgery and risk assessment after SARS-CoV-2 infection: an update A multidisciplinary consensus statement on behalf of the Association of Anaesthetists, Centre for Perioperative Care, Federation of Surgical Specialty Associations, Royal College of Anaesthetists, Royal College of Surgeons of England
    El-Boghdadly, K.
    Cook, T. M.
    Goodacre, T.
    Kua, J.
    Denmark, S.
    McNally, S.
    Mercer, N.
    Moonesinghe, S. R.
    Summerton, D. J.
    [J]. ANAESTHESIA, 2022, 77 (05) : 580 - 587